Gilead Prices $2 Billion of Senior Unsecured Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
Gilead Sciences (GILD) shares oversold argues BofA
September 8, 2023 8:54 AM EDTBofA analyst Geoff Meacham upgraded shares of Gilead Sciences (NASDAQ: GILD) to Buy from Neutral, with a price target of $95, up from $88 per share, in a note to clients on Friday.
The analyst told investors that the pharmaceutical company's HIV drug upside remains... More
